Bennett David A, Schneider Julie A, Aggarwal Neelum T, Arvanitakis Zoe, Shah Raj C, Kelly Jeremiah F, Fox Jacob H, Cochran Elizabeth J, Arends Danielle, Treinkman Anna D, Wilson Robert S
Rush Alzheimer's Disease Center, Chicago, Ill, USA.
Neuroepidemiology. 2006;27(3):169-76. doi: 10.1159/000096129. Epub 2006 Oct 10.
We developed prediction rules to guide the clinical diagnosis of Alzheimer's disease (AD) in two community-based cohort studies (the Religious Orders Study and the Rush Memory and Aging Project). The rules were implemented without informant interviews, neuroimaging, blood work or routine case conferencing. Autopsies were performed at death and the pathologic diagnosis of AD made with a modified version of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria. We compared the positive predictive value of the clinical diagnosis in the two community-based studies to the positive predictive value of the clinical diagnosis of AD made by standard clinical practice in a clinic-based cohort study using AD pathology as the gold standard. Of 306 clinic cases with probable AD, 286 (93.5%) met CERAD neuropathologic criteria for AD; the results were comparable for those with possible AD (51 of 54, 94.4%). Of 141 study subjects with probable AD, 130 (92.2%) met CERAD neuropathologic criteria for AD; the results were lower but acceptable for those with possible AD (26 of 37, 70.3%). The results were similar in secondary analyses using alternate neuropathologic criteria for AD. The clinical diagnosis of AD can be made in community-based studies without the use of informant interviews, neuroimaging, blood work or routine case conferencing. This approach holds promise for reducing the operational costs of epidemiologic studies of aging and AD.
在两项基于社区的队列研究(宗教团体研究和拉什记忆与衰老项目)中,我们制定了预测规则以指导阿尔茨海默病(AD)的临床诊断。这些规则的实施无需进行 informant 访谈、神经影像学检查、血液检查或常规病例会诊。死亡时进行尸检,并根据阿尔茨海默病注册协会(CERAD)标准的修订版做出 AD 的病理诊断。我们将这两项基于社区的研究中临床诊断的阳性预测值与以 AD 病理学为金标准的基于诊所的队列研究中标准临床实践做出的 AD 临床诊断的阳性预测值进行了比较。在 306 例可能患有 AD 的诊所病例中,286 例(93.5%)符合 CERAD 关于 AD 的神经病理学标准;对于可能患有 AD 的病例(54 例中的 51 例,94.4%),结果相当。在 141 例可能患有 AD 的研究对象中,130 例(92.2%)符合 CERAD 关于 AD 的神经病理学标准;对于可能患有 AD 的病例(37 例中的 26 例,70.3%),结果较低但可以接受。使用 AD 的替代神经病理学标准进行的二次分析结果相似。在基于社区的研究中,可以在不进行 informant 访谈、神经影像学检查、血液检查或常规病例会诊的情况下做出 AD 的临床诊断。这种方法有望降低衰老和 AD 流行病学研究的运营成本。